Next Outlook Chat Pharmas Commercial Digital Trends For 2022
![next outlook chat pharma S commercial digital trends 20 next outlook chat pharma S commercial digital trends 20](https://nextpharmasummit.com/Dubrovnik/wp-content/uploads/2021/11/digital-trends-2022_web-1.jpg)
Next Outlook Chat Pharma S Commercial Digital Trends 20 As we approach years end, let’s outlook the upcoming 2022 from perspective of digital and commercial transformation. pharma’s transformation journey is still an ongoing process and in this “pharma chat” we will predict major trends for 2022. join the session to hear experts discuss several major points:. As we approach years end, let’s outlook the upcoming 2022 from perspective of digital and commercial transformation. pharma’s transformation journey is still.
![Webinar Creating pharma S digital And commercial Dna Webinar Creating pharma S digital And commercial Dna](https://nextpharmasummit.com/Dubrovnik/wp-content/uploads/2022/01/za-web_Creating-Pharmas-Digital-and-Commercial-DNA-.jpg)
Webinar Creating Pharma S Digital And Commercial Dna In this pharma chat and together with carefully selected industry leaders, we will speak about major trends for 2022 and beyond. from clinical trials to improving patients life, this chat will answer on all challenges and opportunities of the upcoming 2022. join the session to hear experts discuss several major points:. >watch next pharma chat on > watch on our latest pharma chat: “next outlook chat: pharma's commercial digital trends for 2022“. watch here: lnkd.in d8zgxm i. speaker lineup: davidek herron, mba from roche timothy white from teva pharmaceuticals danilo pagano from lundbeck haider alleg from ferring pharmaceuticals. In 2022, the 15 largest pharmas put down a record setting $138 billion for r&d, a 43% jump from five years prior and a number that represents 18.8% of their recorded sales. A survey conducted by mckinsey in europe shows that the average number of in person contacts between hcps and pharma sales reps was 70 percent lower in september 2020 than before the pandemic. 5 in parallel, hcps’ adoption of digital channels and telemedicine has accelerated for interactions with patients and pharma reps alike.
Comments are closed.